Alzheimer; News from the web:

Biogen posts that BAN2401 met on the ADCOMS secondary endpoint measure in its phase 2 study treating patients with Alzheimer’s.

BAN2401 showed evidence that it could reduce the progression of Alzheimer’s.

The positive update for BAN2401 was a huge surprise, because the failure rate for creating a treatment for Alzheimer’s is 99.6%.

BAN2401 still has to go through a phase 3 study in order to prove that it works in treating patients with Alzheimer’s.

Biogen is not only relying on BAN2401 for Alzheimer’s treatment, it also has another drug in late-stage development for the disease known as Aducanumab.

Read all about it HERE